CytoMed Therapeutics LtdNASDAQ:GDTC
- LAST PRICE2.1000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.8360/ 2
- Ask / Lots2.4800/ 2
- Open / Previous Close0.0000 / 2.1000
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GDTC |
|---|---|---|
| 03:39 ET | 900 | 2.1 |
| 03:52 ET | 200 | 2.1 |
| 03:59 ET | 200 | 2.1 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
CytoMed Therapeutics Ltd | 24.1M | -5.4x | --- |
Curative Biotechnology Inc | 17.6M | -2.7x | --- |
Indaptus Therapeutics Inc | 18.0M | -1.1x | --- |
Minerva Neurosciences Inc | 17.0M | -0.5x | --- |
Nascent Biotech Inc | 17.0M | -6.8x | --- |
Raphael Pharmaceutical Inc | 18.7M | -12.5x | --- |
Company Information
CytoMed Therapeutics Limited is a pre-clinical biopharmaceutical company. The Company is focused on harnessing its licensed proprietary technologies to create cell-based immunotherapies for the treatment of human cancers. The development of its technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies, as well as the clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. It is developing three product candidates: CTM-N2D, iPSC-gdNKT and CTM-GDT. CTM-N2D is its lead product candidate, and it consists of expanded gamma delta T cells grafted with NKG2DL-targeting CAR to enhance anti-cancer cytotoxicity. Its second product candidate, iPSC-gdNKT, utilizes iPSC as a starting material to generate gdNKT, which is a synthetic hybrid of a gamma delta T cell and a NK cell. Its third product candidate, CTM-GDT, consists of expanded allogeneic gamma delta T cells.
Contact Information
- Headquarters
- #08-22 One Commonwealth 1 Commonwealth Lane, Singapore 149544
- Phone
- ---
- Fax
- ---
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $24.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 11.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.39 |
Book Value | $0.04 |
P/E Ratio | -5.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
